News

Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors

Tubulis to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target

Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024

Tubulis publishes article in Molecular Cancer Therapeutics on advantages of its proprietary P5/Tubutecan platform

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Article on Tubulis’ novel ADC conjugation technology P5 makes it to the cover of Chemical Science!

Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer

New Tubulis Paper in Blood highlights potential of next-generation ADC for effective & safe treatment of acute myeloid leukemia

ERP Article: Actualising the Power of Antibody-Drug Conjugates as Cancer Therapeutics

Tubulis moves into the Innovation and Startup Center for Biotechnology IZB in Martinsried

Tubulis Welcomes Mary Ann Lumiqued as Vice President Program Management

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies